Lucid Capital initiated coverage of Innate Pharma (IPHA) with a Buy rating and $8 price target Innate is a clinical-stage biotechnology company focused on developing antibodies and antibody-drug conjugates for oncology indications, the analyst tells investors in a research note. The firm believes the company’s IPH4502 could serve a “key niche” in Padcev-pretreated metastatic urothelial carcinoma, a $1.5B peak sales opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPHA:
- Innate Pharma management to meet with BTIG
- Target initiated, Nike upgraded: Wall Street’s top analyst calls
- Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright
- Innate Pharma SA Reports First Half 2025 Financial Results
- Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating